Summary measures and synthesis of results The principal summary outcome was the relative risk (RR) of several GI adverse events in people with overweight or obesity receiving treatment with GLP-1 RA, including nausea, vomiting, diarrhea, constipation, abdominal distension, upper abdominal pain, abdominal pain, abdominal discomfort, gastroesophageal reflux disease, (GERD), eructation, flatulence, decreased appetite, cholelithiasis, gallstone-related, cholecystitis, acute cholecystitis, acute pancreatitis, viral gastroenteritis, hard feces, and infrequent bowel movements
We may earn a commission from vetted partners at no additional cost to you
This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision
InvictIQ #SocialCare #QualityIntelligence To view or add a comment, sign in "A study published in JAMA Network Open last year found that more than half of all patients with vulvovaginal disorders considered stopping care because of negative experiences with practitioners
J Pediatr Hematol Oncol